Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sumitomo licenses diabetes drug

by Lisa M. Jarvis
November 6, 2017 | A version of this story appeared in Volume 95, Issue 44

Sumitomo Dainippon Pharma will pay $42 million up front for the right to develop Poxel’s type 2 diabetes treatment imeglimin in several Asian countries, including Japan and China. Poxel is in talks with Japanese regulators about the design of three Phase III studies slated to begin there by the end of this year. Poxel is looking for a partner to develop the compound in the U.S. and Europe. While currently marketed diabetes drugs modulate glucose levels, Poxel’s drug increases the amount of glucose excreted in urine.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.